Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New obesity drug delivery methods tested in Early-Stage trial

NCT ID NCT07313761

First seen Jan 06, 2026 · Last updated May 23, 2026 · Updated 21 times

Summary

This early-stage study tests how the body absorbs an experimental weight-loss drug, maridebart cafraglutide, when given as two different types of injections. About 349 adults with overweight or obesity will receive a single dose to compare drug levels and check for side effects. The goal is to find the best way to deliver the medicine for future studies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVERWEIGHT AND OBESITY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Anaheim Clinical Trials

    Anaheim, California, 92801-2658, United States

  • CenExel Collaborative Neuroscience Research, LLC Los Alamitos

    Los Alamitos, California, 90720, United States

  • Clinical Pharmacology Of Miami, LLC

    Miami, Florida, 33172-3161, United States

  • Ohio Clinical Trials, Inc.

    Columbus, Ohio, 43212, United States

Conditions

Explore the condition pages connected to this study.